ArticleJournal of virology2002
Redirecting retroviral tropism by insertion of short, nondisruptive peptide ligands into envelope.
Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 32 citations in OpenAlex.
- Molecular Engineering of Virus Tropism.International journal of molecular sciences · 2024Review
- Polysaccharide-modified scaffolds for controlled lentivirus delivery in vitro and after spinal cord injury.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- Library screening and receptor-directed targeting of gammaretroviral vectors.Future microbiology · 2013Review
- Empowering adult stem cells for myocardial regeneration.Circulation research · 2011Review
- Lentiviral vectors for immune cells targeting.Immunopharmacology and immunotoxicology · 2010Review
- Visualization of targeted transduction by engineered lentiviral vectors.Gene therapy · 2008Article
- Molecular engineering of viral gene delivery vehicles.Annual review of biomedical engineering · 2008Review
- Engineering targeted viral vectors for gene therapy.Nature reviews. Genetics · 2007Review
- Targeting lentiviral vectors to specific cell types in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
- Change of tropism of SL3-2 murine leukemia virus, using random mutational libraries.Journal of virology · 2004Article
- Factors affecting the direct targeting of murine leukemia virus vectors containing peptide ligands in the envelope protein.EMBO reports · 2002Article
- Selective targeting and inducible destruction of human cancer cells by retroviruses with envelope proteins bearing short peptide ligands.Journal of virology · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A potentially powerful approach for in vivo gene delivery is to target retrovirus to specific cells through interactions between cell surface receptors and appropriately modified viral envelope proteins. Previously, relatively large (>100 residues) protein ligands to cell surface receptors have been inserted at or near the N terminus of retroviral envelope proteins. Although viral tropism could be altered, the chimeric envelope proteins lacked full activity, and coexpression of wild-type envelope was required for production of transducing virus. Here we analyze more than 40 derivatives of ecotropic Moloney murine leukemia virus (MLV) envelope, containing insertions of short RGD-containing peptides, which are ligands for integrin receptors. In many cases pseudotyped viruses containing only the chimeric envelope protein could transduce human cells. The precise location, size, and flanking sequences of the ligand affected transduction specificity and efficiency. We conclude that retroviral tropism can be rationally reengineered by insertion of short peptide ligands and without the need to coexpress wild-type envelope.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.